Cargando…

Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias

BACKGROUND: The levels of synaptic markers synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) have been shown to increase early in the cerebrospinal fluid (CSF) of patients with Creutzfeldt-Jakob disease (CJD) and to have prognostic potential. However, no validation studies assessed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bentivenga, Giuseppe Mario, Baiardi, Simone, Mastrangelo, Andrea, Zenesini, Corrado, Mammana, Angela, Polischi, Barbara, Capellari, Sabina, Parchi, Piero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485978/
https://www.ncbi.nlm.nih.gov/pubmed/37684653
http://dx.doi.org/10.1186/s13195-023-01300-y
_version_ 1785102902175465472
author Bentivenga, Giuseppe Mario
Baiardi, Simone
Mastrangelo, Andrea
Zenesini, Corrado
Mammana, Angela
Polischi, Barbara
Capellari, Sabina
Parchi, Piero
author_facet Bentivenga, Giuseppe Mario
Baiardi, Simone
Mastrangelo, Andrea
Zenesini, Corrado
Mammana, Angela
Polischi, Barbara
Capellari, Sabina
Parchi, Piero
author_sort Bentivenga, Giuseppe Mario
collection PubMed
description BACKGROUND: The levels of synaptic markers synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) have been shown to increase early in the cerebrospinal fluid (CSF) of patients with Creutzfeldt-Jakob disease (CJD) and to have prognostic potential. However, no validation studies assessed these biomarkers' diagnostic and prognostic value in a large clinical setting cohort of rapidly progressive dementia. METHODS: In this retrospective study, using commercially available immunoassays, we measured the levels of SNAP-25, Ng, 14–3-3, total-tau (t-tau), neurofilament light chain (NfL), and phospho-tau181 (p-tau) in CSF samples from consecutive patients with CJD (n = 220) or non-prion rapidly progressive dementia (np-RPD) (n = 213). We evaluated and compared the diagnostic accuracy of each CSF biomarker and biomarker combination by receiver operating characteristics curve (ROC) analyses, studied SNAP-25 and Ng CSF concentrations distribution across CJD subtypes, and estimated their association with survival using multivariable Cox regression analyses. RESULTS: CSF SNAP-25 and Ng levels were higher in CJD than in np-RPD (SNAP-25: 582, 95% CI 240–1250 vs. 115, 95% CI 78–157 pg/ml, p < 0.0001; Ng: 841, 95% CI 411–1473 vs. 390, 95% CI 260–766 pg/ml, p < 0.001). SNAP-25 diagnostic accuracy (AUC 0.902, 95% CI 0.873–0.931) exceeded that of 14–3-3 (AUC 0.853, 95% CI 0.816–0.889), t-tau (AUC 0.878, 95% CI 0.845–0.901), and the t-tau/p-tau ratio (AUC 0.884, 95% CI 0.851–0.916). In contrast, Ng performed worse (AUC 0.697, 95% CI 0.626–0.767) than all other surrogate biomarkers, except for NfL (AUC 0.649, 95% CI 0.593–0.705). SNAP-25 maintained a relatively high diagnostic value even for atypical CJD subtypes (AUC 0.792, 95% CI 0.729–0.854). In Cox regression analyses, SNAP-25 levels were significantly associated with survival in CJD (hazard ratio [HR] 1.71 95% CI 1.40–2.09). Conversely, Ng was associated with survival only in the most rapidly progressive CJD subtypes (sCJD MM(V)1 and gCJD M1) (HR 1.81 95% CI 1.21–2.93). CONCLUSIONS: In the clinical setting, CSF SNAP-25 is a viable alternative to t-tau, 14–3-3, and the t-tau/p-tau ratio in discriminating the CJD subtypes from other RPDs. Additionally, SNAP-25 and, to a lesser extent, Ng predict survival in CJD, showing prognostic power in the range of CSF t-tau/14–3-3 and NfL, respectively. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01300-y.
format Online
Article
Text
id pubmed-10485978
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104859782023-09-09 Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias Bentivenga, Giuseppe Mario Baiardi, Simone Mastrangelo, Andrea Zenesini, Corrado Mammana, Angela Polischi, Barbara Capellari, Sabina Parchi, Piero Alzheimers Res Ther Research BACKGROUND: The levels of synaptic markers synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) have been shown to increase early in the cerebrospinal fluid (CSF) of patients with Creutzfeldt-Jakob disease (CJD) and to have prognostic potential. However, no validation studies assessed these biomarkers' diagnostic and prognostic value in a large clinical setting cohort of rapidly progressive dementia. METHODS: In this retrospective study, using commercially available immunoassays, we measured the levels of SNAP-25, Ng, 14–3-3, total-tau (t-tau), neurofilament light chain (NfL), and phospho-tau181 (p-tau) in CSF samples from consecutive patients with CJD (n = 220) or non-prion rapidly progressive dementia (np-RPD) (n = 213). We evaluated and compared the diagnostic accuracy of each CSF biomarker and biomarker combination by receiver operating characteristics curve (ROC) analyses, studied SNAP-25 and Ng CSF concentrations distribution across CJD subtypes, and estimated their association with survival using multivariable Cox regression analyses. RESULTS: CSF SNAP-25 and Ng levels were higher in CJD than in np-RPD (SNAP-25: 582, 95% CI 240–1250 vs. 115, 95% CI 78–157 pg/ml, p < 0.0001; Ng: 841, 95% CI 411–1473 vs. 390, 95% CI 260–766 pg/ml, p < 0.001). SNAP-25 diagnostic accuracy (AUC 0.902, 95% CI 0.873–0.931) exceeded that of 14–3-3 (AUC 0.853, 95% CI 0.816–0.889), t-tau (AUC 0.878, 95% CI 0.845–0.901), and the t-tau/p-tau ratio (AUC 0.884, 95% CI 0.851–0.916). In contrast, Ng performed worse (AUC 0.697, 95% CI 0.626–0.767) than all other surrogate biomarkers, except for NfL (AUC 0.649, 95% CI 0.593–0.705). SNAP-25 maintained a relatively high diagnostic value even for atypical CJD subtypes (AUC 0.792, 95% CI 0.729–0.854). In Cox regression analyses, SNAP-25 levels were significantly associated with survival in CJD (hazard ratio [HR] 1.71 95% CI 1.40–2.09). Conversely, Ng was associated with survival only in the most rapidly progressive CJD subtypes (sCJD MM(V)1 and gCJD M1) (HR 1.81 95% CI 1.21–2.93). CONCLUSIONS: In the clinical setting, CSF SNAP-25 is a viable alternative to t-tau, 14–3-3, and the t-tau/p-tau ratio in discriminating the CJD subtypes from other RPDs. Additionally, SNAP-25 and, to a lesser extent, Ng predict survival in CJD, showing prognostic power in the range of CSF t-tau/14–3-3 and NfL, respectively. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01300-y. BioMed Central 2023-09-08 /pmc/articles/PMC10485978/ /pubmed/37684653 http://dx.doi.org/10.1186/s13195-023-01300-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bentivenga, Giuseppe Mario
Baiardi, Simone
Mastrangelo, Andrea
Zenesini, Corrado
Mammana, Angela
Polischi, Barbara
Capellari, Sabina
Parchi, Piero
Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias
title Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias
title_full Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias
title_fullStr Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias
title_full_unstemmed Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias
title_short Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias
title_sort diagnostic and prognostic value of cerebrospinal fluid snap-25 and neurogranin in creutzfeldt-jakob disease in a clinical setting cohort of rapidly progressive dementias
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485978/
https://www.ncbi.nlm.nih.gov/pubmed/37684653
http://dx.doi.org/10.1186/s13195-023-01300-y
work_keys_str_mv AT bentivengagiuseppemario diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias
AT baiardisimone diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias
AT mastrangeloandrea diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias
AT zenesinicorrado diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias
AT mammanaangela diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias
AT polischibarbara diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias
AT capellarisabina diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias
AT parchipiero diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias